Akademik Veri Yönetim Sistemi
8th Drug Chemistry Conference, Antalya, Türkiye, 27 Şubat - 01 Mart 2020, ss.266
Breast cancer is the most common form of cancer in women worldwide, about 2 million new cases
diagnosed and 627,000 patients died in 2018 [1]. Combination therapy is widely used in the treatment
of cancer. The main reason for using anticancer treatment methods together is to obtain a better
response while limiting adverse events [2].
Gambogic acid is a Chinese traditional medicine which is originally derived from resin of Garcinia
hanburyi. Many studies have reported that gambogic acid has several biological properties, such as
anti-proliferative, anti-metastasis, anti-oxidant and anti-inflammatory [3, 4]. Gambogic acid has been
approved by the Chinese Food and Drug Administration for phase II clinical trial in cancer therapy in
2012 [5].
Roche developed capecitabine was approved by the FDA as an anti-cancer (antineoplastic, cytotoxic)
chemotherapy drug for patients with colorectal and breast cancer. Capecitabine is a fluoropyrimidine
carbamate primarily metabolized by thymidine phosphorylase and converted to Fluorouracil that is an
antimetabolite with activity against numerous types of neoplasms by three enzymatic steps [6].
In this research, we investigated the synergistic effect of capecitabine and gambogic acid on breast
cancer MDA-MB-453 cell by XTT method and the combination index (CI) values were calculated by
CompuSyn software. The synergy was examined with Bcl2, Caspase-3, caspase-9 and Bax mRNA and
protein levels by quantitative real-time PCR and enzyme-linked immunosorbent assay (ELISA) in the
capecitabine and gambogic acid-applied cells.